Publications by authors named "Kim Edmonds"

Claim this Profile
T
Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx Renal.
Ángel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, Anne-Laure Cattin, Charlotte Spencer, Kim Edmonds

Cancer Discov· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal.
Ángel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, Anne-Laure Cattin, Charlotte Spencer, Kim Edmonds

Cancer Discov· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
James Larkin, Richard Marais, Nuria Porta, David Gonzalez de Castro, Lisa Parsons, Kim Edmonds

Cell Rep Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Lavinia Spain, Alexander Coulton, Irene Lobon, Andrew Rowan, Desiree Schnidrig, Kim Edmonds

Cancer Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Mary Y Wu, Scott T C Shepherd, Annika Fendler, Edward J Carr, Lewis Au, Kim Edmonds

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
Sophie Merrick, Matthew Nankivell, Matteo Quartagno, Caroline S Clarke, Nalinie Joharatnam-Hogan, Kim Edmonds

Contemp Clin Trials· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Annika Fendler, Scott T C Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Kim Edmonds

Cell Rep Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Annika Fendler, Scott T C Shepherd, Lewis Au, Katalin A Wilkinson, Mary Wu, Kim Edmonds

Cancer Cell· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
Annika Fendler, Scott T C Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Kim Edmonds

Lancet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Annika Fendler, Scott T C Shepherd, Lewis Au, Katalin A Wilkinson, Mary Wu, Kim Edmonds

Cancer Cell· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.
Annika Fendler, Scott T C Shepherd, Lewis Au, Katalin A Wilkinson, Mary Wu, Kim Edmonds

Nat Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Annika Fendler, Scott T C Shepherd, Lewis Au, Katalin A Wilkinson, Mary Wu, Kim Edmonds

Nat Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Annika Fendler, Lewis Au, Scott T C Shepherd, Fiona Byrne, Maddalena Cerrone, Kim Edmonds

Nat Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Gordon Beattie, Kim Edmonds

Cancer Cell· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Annika Fendler, Lewis Au, Scott T C Shepherd, Fiona Byrne, Maddalena Cerrone, Kim Edmonds

Res Sq· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Lewis Au, Annika Fendler, Scott T C Shepherd, Karolina Rzeniewicz, Maddalena Cerrone, Kim Edmonds

Nat Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
Aine O'Reilly, Peta Hughes, Jasmine Mann, Zhuangming Lai, Jhia Jiat Teh, Kim Edmonds

Support Care Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Heike Seifert, Rosalie Fisher, Juan Martin-Liberal, Kim Edmonds, Peta Hughes

Melanoma Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Rishika Sinha, Kim Edmonds, Julia Newton-Bishop, Martin Gore, James Larkin

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Kim Edmonds, Diana Hull, Andrea Spencer-Shaw, José Koldenhof, Maria Chrysou

Eur J Oncol Nurs· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing adverse events associated with sorafenib in renal cell carcinoma.
Kim Edmonds, Andrea Spencer-Shaw

Br J Nurs· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
Michelle L Harrison, Eva Obermueller, Nick R Maisey, Susan Hoare, Kim Edmonds

J Clin Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis